Vertex Pharmaceuticals bags UK approval for ALYFTREK, a next-generation cystic fibrosis treatment
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor), a next-generation CFTR modulator treatment developed by Vertex Pharmaceuticals ... Read More
Vertex secures FDA approval for non-opioid pain treatment JOURNAVX
Vertex Pharmaceuticals Incorporated has achieved a significant milestone in the field of pain management with the FDA approval of JOURNAVX (suzetrigine), a first-in-class non-opioid pain ... Read More
Vertex Pharmaceuticals’ suzetrigine approved for FDA review: A breakthrough in pain management
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced a pivotal advancement in the treatment of acute pain. The U.S. Food and Drug Administration (FDA) has officially ... Read More
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9bn in strategic expansion
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN) have announced a definitive agreement ... Read More
FDA approves Vertex and CRISPR Therapeutics’ CASGEVY for sickle cell disease
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics have announced a significant milestone in medical science with the U.S. Food and Drug Administration's (FDA) approval of CASGEVY ... Read More
Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals
Vertex Pharmaceuticals is set to launch its cystic fibrosis drug KALYDECO (ivacaftor) in New Zealand, which will be available to eligible patients from next month. ... Read More